Press release
HER2+ Gastric Cancer Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Pfizer, Bayer, Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology
DelveInsight's "HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the HER2+ Gastric Cancer, historical and forecasted epidemiology as well as the HER2+ Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of HER2+ Gastric Cancer, offering comprehensive insights into the HER2+ Gastric Cancer revenue trends, prevalence, and treatment landscape. The report delves into key HER2+ Gastric Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging HER2+ Gastric Cancer therapies. Additionally, we cover the landscape of HER2+ Gastric Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of HER2+ Gastric Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the HER2+ Gastric Cancer space.
To Know in detail about the HER2+ Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2+ Gastric Cancer Market Forecast [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the HER2+ Gastric Cancer Market Report:
*
The HER2+ gastric cancer market in the 7MM is anticipated to increase from USD 702 million in 2025, growing at a CAGR of 14.20% and reaching approximately USD 2,318 million by 2034.
*
In November 2025, DPTX3186, a first-in-class oral condensate-modulating agent (c-mod), has received FDA fast track designation for the treatment of gastric cancer.
*
In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as a first-line treatment for GEA in 2026. The company also plans to expand its market strategy for zanidatamab during the same year.
*
In February 2025, AstraZeneca expects the Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial-targeting metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA-to provide a data readout in 2026.
*
In February 2025, AstraZeneca plans to initiate first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer and GEJ adenocarcinoma in Q1 2025, with data expected to become available post-2026.
*
AstraZeneca expects data from the DESTINY-Gastric04 (NCT04704934) trial-evaluating HER2+ gastric cancer or GEJ adenocarcinoma patients who have progressed following a trastuzumab-containing regimen and have not received further systemic therapy-to be available in H2 2025.
*
In January 2025, ALX Oncology reported positive updated results from the ASPEN-06 Phase II trial at the 2025 ASCO Gastrointestinal Cancers Symposium, showing that their investigational CD47-blocker, evorpacept, delivers a durable clinical response and has a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric or GEJ cancer.
*
In 2024, the HER2+ gastric cancer market was largest in the US among the 7MM, valued at approximately USD 300 million, and is projected to grow further by 2034.
*
In 2024, Trastuzumab plus-minus Chemotherapy generated the highest revenue among existing therapies for HER2+ gastric cancer in the United States, amounting to approximately USD 140 million.
*
Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan) is currently the only approved treatment for advanced or metastatic HER2+ gastric cancer in the second-line (2L) setting, having received accelerated approval in January 2021. For first-line (1L) therapy, ENHERTU is joined by KEYTRUDA (pembrolizumab) and HERCEPTIN (trastuzumab) as approved treatment options for HER2+ gastric cancer.
*
Key HER2+ Gastric Cancer Companies: Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharmaceuticals, BeiGene, and Zymeworks, Shanghai Henlius Biotech and AbClon, AstraZeneca, ALX Oncology, Pfizer, Bayer, Artiva Biotherapeutics and GC Cell, KLUS Pharma, Shanghai Miracogen, Enliven Therapeutics, Ambrx and NovoCodex, Mersana Therapeutics and GSK, SystImmune, and others
*
Key HER2+ Gastric Cancer Therapies: KEYTRUDA (pembrolizumab), ENHERTU (trastuzumab deruxtecan), ZIIHERA (zanidatamab), HLX22 (AC101), Rilvegostomig, Evorpacept (ALX148), TUKYSA (tucatinib), AY2927088, AB-201 (GCC2003,HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others
*
The HER2+ Gastric Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2+ Gastric Cancer pipeline products will significantly revolutionize the HER2+ Gastric Cancer market dynamics.
*
In the United States, approximately 15% of patients with advanced gastric cancer and 30% of those with advanced gastroesophageal junction (GEJ) cancer exhibit HER2-positive tumors.
*
In 2024, the United States recorded approximately 6,650 new cases of HER2+ gastric cancer, while Japan reported the highest number of cases, totaling around 27,000.
HER2+ Gastric Cancer Overview
HER2+ Gastric Cancer is a subtype of gastric (stomach) cancer characterized by the overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is involved in cell growth and division, and its abnormal activation can drive tumor progression. Patients with HER2+ gastric cancer often have more aggressive disease, but the presence of HER2 also makes them eligible for targeted therapies, such as trastuzumab, which specifically attack HER2-positive tumor cells, improving treatment outcomes compared to standard chemotherapy alone.
Get a Free sample for the HER2+ Gastric Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
HER2+ Gastric Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
HER2+ Gastric Cancer Epidemiology Segmentation:
The HER2+ Gastric Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of HER2+ Gastric Cancer
*
Prevalent Cases of HER2+ Gastric Cancer by severity
*
Gender-specific Prevalence of HER2+ Gastric Cancer
*
Diagnosed Cases of Episodic and Chronic HER2+ Gastric Cancer
Download the report to understand which factors are driving HER2+ Gastric Cancer epidemiology trends @ HER2+ Gastric Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
HER2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2+ Gastric Cancer market or expected to get launched during the study period. The analysis covers HER2+ Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the HER2+ Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
HER2+ Gastric Cancer Therapies and Key Companies
*
KEYTRUDA (pembrolizumab): Merck
*
ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca
*
ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks
*
HLX22 (AC101): Shanghai Henlius Biotech and AbClon
*
Rilvegostomig: AstraZeneca
*
Evorpacept (ALX148): ALX Oncology
*
TUKYSA (tucatinib): Pfizer
*
BAY2927088: Bayer
*
AB-201 (GCC2003,HER2 CAR-NK): Artiva Biotherapeutics and GC Cell
*
A166 (Trastuzumab botidotin): KLUS Pharma
*
MRG002: Shanghai Miracogen
*
AIDIXI (disitamab vedotin): Pfizer
*
BAY2701439: Bayer
*
ELVN-002: Enliven Therapeutics
*
ARX788: Ambrx and NovoCodex
*
XMT-2056: Mersana Therapeutics and GSK
*
BL-M07D1: SystImmune
Discover more about therapies set to grab major HER2+ Gastric Cancer market share @ HER2+ Gastric Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
HER2+ Gastric Cancer Market Drivers
*
Increasing prevalence of advanced and metastatic gastric and gastroesophageal junction (GEJ) cancers.
*
Rising adoption of HER2-targeted therapies such as ENHERTU, HERCEPTIN, and KEYTRUDA.
*
Advances in diagnostic testing for HER2 status, enabling personalized treatment approaches.
*
Growing awareness among healthcare providers about precision medicine and biomarker-driven therapies.
*
Supportive regulatory pathways and accelerated approvals for novel HER2-targeted therapies.
HER2+ Gastric Cancer Market Barriers
*
Limited patient population, as only a subset of gastric and GEJ cancers are HER2-positive.
*
High cost of targeted therapies, restricting access in low- and middle-income regions.
*
Resistance development and limited efficacy in some patients, requiring combination therapies.
*
Stringent regulatory requirements and long approval timelines in certain regions.
*
Lack of awareness and diagnostic infrastructure in emerging markets.
Scope of the HER2+ Gastric Cancer Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key HER2+ Gastric Cancer Companies: Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharmaceuticals, BeiGene, and Zymeworks, Shanghai Henlius Biotech and AbClon, AstraZeneca, ALX Oncology, Pfizer, Bayer, Artiva Biotherapeutics and GC Cell, KLUS Pharma, Shanghai Miracogen, Enliven Therapeutics, Ambrx and NovoCodex, Mersana Therapeutics and GSK, SystImmune, and others
*
Key HER2+ Gastric Cancer Therapies: KEYTRUDA (pembrolizumab), ENHERTU (trastuzumab deruxtecan), ZIIHERA (zanidatamab), HLX22 (AC101), Rilvegostomig, Evorpacept (ALX148), TUKYSA (tucatinib), AY2927088, AB-201 (GCC2003,HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others
*
HER2+ Gastric Cancer Therapeutic Assessment: HER2+ Gastric Cancer current marketed and HER2+ Gastric Cancer emerging therapies
*
HER2+ Gastric Cancer Market Dynamics: HER2+ Gastric Cancer market drivers and HER2+ Gastric Cancer market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
HER2+ Gastric Cancer Unmet Needs, KOL's views, Analyst's views, HER2+ Gastric Cancer Market Access and Reimbursement
To know more about HER2+ Gastric Cancer companies working in the treatment market, visit @ HER2+ Gastric Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. HER2+ Gastric Cancer Market Report Introduction
2. Executive Summary for HER2+ Gastric Cancer
3. SWOT analysis of HER2+ Gastric Cancer
4. HER2+ Gastric Cancer Patient Share (%) Overview at a Glance
5. HER2+ Gastric Cancer Market Overview at a Glance
6. HER2+ Gastric Cancer Disease Background and Overview
7. HER2+ Gastric Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of HER2+ Gastric Cancer
9. HER2+ Gastric Cancer Current Treatment and Medical Practices
10. HER2+ Gastric Cancer Unmet Needs
11. HER2+ Gastric Cancer Emerging Therapies
12. HER2+ Gastric Cancer Market Outlook
13. Country-Wise HER2+ Gastric Cancer Market Analysis (2020-2034)
14. HER2+ Gastric Cancer Market Access and Reimbursement of Therapies
15. HER2+ Gastric Cancer Market Drivers
16. HER2+ Gastric Cancer Market Barriers
17. HER2+ Gastric Cancer Appendix
18. HER2+ Gastric Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-gastric-cancer-market-revenue-to-expand-significantly-by-2034-states-delveinsight-report-pfizer-bayer-merck-daiichi-sankyo-and-astrazeneca-jazz-pharma-beigene-zymeworks-alx-oncology]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Gastric Cancer Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Pfizer, Bayer, Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology here
News-ID: 4310258 • Views: …
More Releases from ABNewswire
Actress Janet Lopez Featured on Access Daily and Winner of Mario Lopez Look-Alik …
Image: https://www.abnewswire.com/upload/2025/12/7c685e1579e483d04e5c4dad5cb16c5e.jpg
Los Angeles, CA - Actress Janet Lopez is making headlines following her recent appearance on Access Daily, where she discussed her work, her career, and the excitement around her latest projects. Lopez also delighted audiences by winning the Mario Lopez Look-Alike Contest, adding a fun and memorable moment to her media presence.
Lopez is now preparing for her next film project, Hospital Chaos, a comedic and fast-paced story set inside…
GLP-1 Agonists Market to Reach USD 170.75 Billion by 2033 Driven by Manufacturin …
Browse 400 market data Tables and 45 Figures spread through 300 Pages and in-depth TOC on "GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033
The global GLP-1 Agonists Market, valued at US$53.74 billion in 2024, grew to US$64.42 billion in 2025 and is projected to surge to US$170.75 billion…
In Vitro Diagnostics Market: Rising to USD 157.63 Billion by 2030 Amid Personali …
Some of the prominent players operating in the market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US)
The global In Vitro Diagnostics (IVD) Market, valued at US$100,769.3 million in 2024, is poised for strong expansion, reaching US$109,065.5 million in 2025 and an impressive US$157,632.5 million by 2030 at a 7.6% CAGR. As healthcare systems worldwide transition toward…
Remote Patient Monitoring Market: Global Growth, Key Drivers, and Future Outlook …
Browse 354 market data Tables and 64 Figures spread through 395 Pages and in-depth TOC on "Remote Patient Monitoring (RPM) Market by Offering (Software, integrated device), Device (Wearable, implants, handheld), Function (Cardiac, Glucose, Multiparameter), Application (Diabetes, Cardio, Neuro), End user, & Region - Global Forecast to 2030
The Remote Patient Monitoring (RPM) Market is experiencing strong global growth as healthcare systems shift toward home-based care, chronic disease management, and digital health…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
